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amine neurotransmitter degrading enzyme, is closely associated
with neurological and psychiatric disorders. However, its role in
cancer progression remains unknown.
Methods: Hepatocellular carcinoma (HCC) tissue arrays (n = 254)
were used to investigate the correlation between MAOA expres-
sion and clinicopathological ﬁndings. In vitro invasion and anoikis
assays, and in vivo intrahepatic and lung metastasis models were
used to determine the role of MAOA in HCC metastasis. Quantita-
tive real-time PCR, western blotting, immunohistochemical stain-
ing and HPLC analysis were performed to uncover the mechanism
of MAOA in HCC.
Results:We found that MAOA expression was signiﬁcantly
downregulated in 254 clinical HCC samples and was closely cor-
related with cancer vasoinvasion, metastasis, and poor progno-
ses. We then demonstrated that MAOA suppressed
norepinephrine/epinephrine (NE/E)-induced HCC invasion and
anoikis inhibition, and uncovered that the effects of NE/E onJournal of Hepatology 20
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(ADRA1A) and beta 2 adrenergic receptors (ADRB2). In addition
to the canonical signaling pathway, which is mediated via adren-
ergic receptors (ADRs), we found that ADR-mediated EGFR trans-
activation was also involved in NE-induced HCC invasion and
anoikis inhibition. Notably, we found that MAOA could synergize
with EGFR inhibitors or ADR antagonists to abrogate NE-induced
HCC behaviors.
Conclusions: Taken together, the results of our study may pro-
vide insights into the application of MAOA as a novel predictor
of clinical outcomes and indicate that increasing MAOA expres-
sion or enzyme activity may be a new approach that can be used
for HCC treatment.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Cancer metastasis may be affected by many factors, including
intracellular signaling molecules and extracellular components,
such as cytokines; the extracellular matrix; and neurotransmit-
ters [1,2]. Growing evidence indicates that the nervous system
plays important roles in cancer progression [3]. Recently, it has
been reported that sympathetic and parasympathetic nervous
systems contribute to cancer development and dissemination in
prostate cancer [4]. Adrenergic neurotransmitters, norepineph-
rine (NE) and epinephrine (E), have been reported to promote
cancer cell migration and invasion in multiple types of cancer
via b-ARs [5,6]. Furthermore, besides cancer cells, stromal cells
in the tumor microenvironment could also be affected by the ner-
vous system [7,8]. Studies of ovarian cancer have demonstrated
that NE/E may contribute to tumor progression by promoting
angiogenesis [9]. By a large-scale cDNA transfection screening,
our previous study revealed that many neurotransmitter recep-
tor-related genes are closely associated with cancer cell prolifera-
tion and survival [10]. We further found that acetylcholinesterase
acts as a tumor growth suppressor in regulating cell proliferation,14 vol. 60 j 1225–1234
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the relevant signaling pathway and the drug sensitivity of HCC
cells [11].
The major NE/E degrading enzyme is monoamine oxidase A
(MAOA), which catalyzes the oxidative deamination of monoam-
ines. In addition to neurons and astrocytes, MAOA is also
expressed in the liver, digestive tract, and placenta [12,13]. MAOA
is closely associated with human emotional and mental activity.
Several reports have demonstrated that reduced MAOA activity is
related to human social and criminal behaviors [14–16]. Few
studies have addressed the role of MAOA in cancer except for
prostate cancer and cholangiocarcinoma, whereas diverse roles
were displayed [17–19]. By analyzing three independent HCC
microarray datasets from the GEO database, we found that MAOA
mRNA levels are signiﬁcantly downregulated in the majority of
HCC tissues compared to non-tumorous liver tissues.
In the present study, we found that MAOA was signiﬁcantly
downregulated in HCC by epigenetic alteration and the expres-
sion ofMAOAwas closely associated with the key events of tumor
metastasis. Further investigations have demonstrated that in
addition to the canonical signaling pathway mediated via ADRs,
NE-induced HCC invasion and anoikis inhibition are partially
mediated by EGFR transactivation. Therefore, EGFR inhibitors,
antagonists of ADRs or MAOA overexpression can synergistically
inhibit NE-induced HCC metastatic behaviors, thereby indicating
that MAOAmay be a metastatic and prognostic predictor. In addi-
tion, increasing MAOA expression or enzyme activity may be a
novel approach that can be used for HCC therapy.Materials and methods
Materials and methods of cell culture, clinical samples, in vitro assays, in vivo
studies, and statistical analysis are provided in Supplementary Materials and
methods.Results
MAOA is downregulated in HCC and is closely related to blood vessel
invasion and patient prognoses
By analyzing three independent HCC microarray datasets from
the GEO database, we found that the mRNA levels of MAOA were
signiﬁcantly downregulated in the majority of HCC tissues com-
pared to non-tumorous tissues (Table 1). In the present study,
we examined the expression levels of MAOA in 254 HCC and cor-
responding non-cancerous liver (CNL) tissues using immunohis-
tochemical staining (Fig. 1A). The results indicated that MAOA
was downregulated in 70.5% (179/254) of HCC patients
(Fig. 1B). In HCC cell lines, MAOA expression levels were lower
in most tested HCC cells, with the exceptions of SK-Hep1 and
SNU-398, compared to immortalized human liver L-O2 cells
(Supplementary Fig. 1A and B).
To investigate the clinical signiﬁcance of MAOA in HCC, we
analyzed the MAOA expression status with respect to various
pathological parameters in 254 HCC patients. The results indi-
cated that MAOA expression in HCC tissues were closely corre-
lated with blood vessel invasion, tumor thrombus formation,
tumor encapsulation, TNM stage, tumor size, alpha-fetoprotein
levels, and tumor differentiation (Table 2). Furthermore, high
MAOA expression was associated with improved overall survival1226 Journal of Hepatology 2014(OS) (Fig. 1C) and disease-free survival (DFS) (Fig. 1D). Taken
together, our data strongly implied that MAOA may act as an
indicator of HCC metastasis and prognosis. To further investigate
the relevance of MAOA with HCC metastasis, we collected normal
liver, CNL, HCC, and tumor thrombus tissues from the same
patients and characterized MAOA expression in these tissues.
As demonstrated in Fig. 1E, MAOA expression was higher in the
normal liver tissues and CNL, and lower in the HCC and tumor
thrombus samples. These results were further conﬁrmed by wes-
tern blotting (Fig. 1F). Using 5-aza-20-deoxycytidine (DAC), a spe-
ciﬁc methyltransferase inhibitor, and Trichostatin A (TSA), a
histone deacetylase inhibitor, we found that methylation
occurred in all of 5 tested HCC cell lines, and histone acetylation
existed in 3 of them. These data indicated that epigenetic meth-
ylation and histone acetylation suppress the expression level of
MAOA in HCC (Supplementary Fig. 2).
MAOA suppresses NE/E-induced HCC cell invasion and anoikis
inhibition in vitro and HCC metastasis in vivo
Previous studies have demonstrated noticeable effects of NE/E on
cancer cell invasion and anoikis [6,7], but the role of the adrener-
gic system in HCC cell behavior has not been reported. In our
study, we found that NE/E promoted HCC invasion and prevented
anoikis in both SMMC-7721 and MHCC-97L cells (Fig. 2A and B).
And these effects were completely abrogated by MAOA overex-
pression (Fig. 2A and B and Supplementary Fig. 1C). However,
NE/E had no effect on HCC cell proliferation (Supplementary
Fig. 3).
To further explore the role of MAOA in cancer progression
in vivo, Lenti-vector or Lenti-MAOA cells (SMMC-7721) were
orthotopically injected into nude mice to assess intrahepatic
metastases, and intravenously transplanted to assess distant
metastases. Histological examinations of the liver and lung tis-
sues indicated that mice transplanted with MAOA overexpressing
cells had fewer intrahepatic and pulmonary metastatic nodules
than those transplanted with control cells (Fig. 2C and D).
To further conﬁrm that MAOA is a metastasis suppressor
in vivo, we used a speciﬁc MAOA inhibitor, clorgyline, to inhibit
endogenous MAOA activity in HCC cells in nude mice. SK-Hep1,
an HCC cell line with high endogenous MAOA, was orthotopically
or intravenously transplanted into nude mice. Clorgyline (0.2 mg)
was then intraperitoneally injected into nude mice twice per
week and the animals were sacriﬁced 6 weeks later. The ortho-
topically transplanted mice treated with clorgyline had greater
numbers of intrahepatic metastatic nodules than those treated
with the vehicle (Fig. 2E). No pulmonary metastatic nodules were
observed in the intravenous transplantation models.
MAOA reduces NE/E levels in vitro and MAOA expression is inversely
correlated with NE/E levels in HCC tissues
To explore the mechanism underlying MAOA suppresses NE/E-
induced HCC cell behavior, we tested whether MAOA can remove
NE/E from the HCC microenvironment. After 6 h incubation, the
concentrations of exogenous NE/E were determined to be
approximately 30% less in MAOA overexpressing cells than in
control cells (Supplementary Fig. 4).
Further, NE/E levels in HCC tissues were found to be inversely
correlated with MAOA expression (Fig. 3A and B). Interestingly,
our data also indicated that the predominant catecholamine neu-vol. 60 j 1225–1234
Table 1. Analysis of MAOA expression in 3 independent HCC microarray data from GEO database.
GSE serials HCC/CNL MAOA expression
Cases Down Up
GSE6764 Early or advanced HCC compared with normal liver tissue 35 33 (94%) 2 (6%)
GSE11260 HCC compared with adjacent non-tumor tissue 32 26 (81%) 6 (19%)
GSE14323 Liver tissue with HCC compared with normal liver tissue 55 55 (100%) 0 (0%)
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Fig. 1. MAOA is down-regulated and is closely related to patient prognosis in hepatocellular carcinoma (HCC). (A) The immunohistochemical staining of MAOA in HCC
and corresponding noncancerous liver (CNL) tissues. Scale bars, 10 lm. (B) The expression of MAOA was down-regulated in 70.5% of HCC patients. (C) Kaplan-Meier analysis
of OS for the expression of MAOA. p = 0.002. (D) Kaplan-Meier analysis of DFS for the expression of MAOA. p = 0.010. (E) The immunohistochemical staining of MAOA in
HCC, CNL, normal liver and thrombus tissues. Scale bars, 10 lm. (F) Western blotting analysis of MAOA expression in HCC, CNL, normal liver and thrombus tissues. GAPDH
was used as a loading control.
JOURNAL OF HEPATOLOGYrotransmitter in HCC tissues was NE, which was 98.9 times
higher than the levels of E (Fig. 3C). Dopamine and serotonin
were undetectable in HCC tissues. Additionally, MAOA was also
detected in the cell culture supernatants of overexpressed
SMMC-7721 or MHCC-97L cells, suggesting that MAOA can
degrade extracellular NE/E in the HCC microenvironment
(Fig. 3D).
NE/E promote HCC cell invasion via a1A- and b2-ADRs and prevent
anoikis via the b2-ADR
To identify the ADR subtypes that mediate NE/E-induced HCC cell
invasion and anoikis inhibition, we examined the expression pat-
terns of ADRs by RT-PCR and western blot analysis. We foundJournal of Hepatology 2014that ADRA1A and ADRB2 are the predominate subtypes of 9 ADRs
in HCC tissues and cell lines (Supplementary Fig. 5A–D), which is
consistent with previous reports indicating that the ADRA1A- and
ADRB2-subtypes are the predominant ADRs that are expressed in
the human liver plasma membrane [20].
We further explored the functional roles of ADRA1A and
ADRB2 in NE/E-induced HCC cell invasion and anoikis inhibition.
Prazosin (an a1-ADR antagonist, 100 nmol/L) and ICI118551 (a
b2-ADR antagonist, 100 nmol/L) were applied. ICI118551 can
effectively inhibit NE/E-induced SMMC-7721 cell invasion and
anoikis inhibition, while prazosin can only inhibit NE/E-induced
SMMC-7721 cell invasion (Fig. 3E and Supplementary Fig. 6A).
Similar effects were observed using small interfering RNA (siRNA)
to downregulate the expression of ADRA1A and ADRB2 (Supple-vol. 60 j 1225–1234 1227
Table 2. Correlation of the clinicopathological ﬁndings with MAOA
expression.
Variable MAOA (n)
High Low p value
Age
≤50 yr 65 55 0.105
>50 yr 86 48
Gender
Female 20 14 0.936
Male 131 89
Hepatitis history
Yes 117 70 0.752
No 10 5
Gamma-glutamytransferase
≤50 (U/L) 42 20 0.340
>50 (U/L) 85 55
Alpha-fetoprotein
≤20 ng/ml 52 15 0.002
>20 ng/ml 75 60
Glu
≤7 mmol/L 110 68 0.390
>7 mmol/L 17 7
Lobe
Right 81 51 0.795
Left 29 16
Right & Left 17 8
Tumor multiplicity
Single 109 60 0.279
Multiple 18 15
Tumor satellite
Yes 17 16 0.140
No 110 59
*Tumor encapsulation
Incomplete 62 50 0.014
Complete 65 25
**Tumor thrombus
Yes 16 28 <0.001
No 111 47
Tumor differentiation
I 6 1 0.003
II 74 32
III 71 70
**Vascular invasion
Yes 36 64 <0.001
No 115 39
Tumor size
≤5 cm 98 30 <0.001
>5 cm 53 73
TNM stage
I 105 49 <0.001
II 22 7
III 24 47
Pearson’s v2 test was used.
Research Articlementary Fig. 5E). ADRB2 siRNA effectively inhibited NE/E-
induced SMMC-7721 cell invasion and anoikis inhibition, while1228 Journal of Hepatology 2014ADRA1A siRNA only inhibited NE/E-induced SMMC-7721 cell
invasion (Fig. 3G and Supplementary Fig. 6C).
Another HCC cell line, MHCC-97L, in which only the b subtype
of ADRs are expressed was used to determine predominant func-
tional ADR subtypes (Supplementary Fig. 5C). The b2-AR antago-
nist ICI118551 effectively inhibited NE/E-induced MHCC-97L cell
invasion and anoikis inhibition, while the a1-AR antagonist, pra-
zosin, has no signiﬁcant effects on NE/E-induced cell invasion or
anoikis inhibition (Fig. 3F and Supplementary Fig. 6B). Similar
effects were observed using siRNA interference (Fig. 3H and Sup-
plementary Figs. 5E and 6D).
These results indicated that NE/E-induced HCC cell invasion is
mediated by both a1- and b2-ADRs, but anoikis inhibition is only
mediated by b2-ADRs.MAOA suppresses the ADR-mediated transactivation of EGFR
signaling
Recent studies have shown that G protein-coupled receptors
(GPCRs), including ADRs, transactivate EGFR signaling to modu-
late biological functions under speciﬁc physiological or patholog-
ical conditions [21]. Activation of GPCRs results in
metalloprotease-dependent release of EGF-like ligands (HB-EGF,
amphiregulin, TGF-alpha, etc.), which in turn activate EGFR and
intracellular downstream signal [22]. NE/ADR-mediated EGFR
transactivation was observed in several HCC cell lines and was
more signiﬁcant in cells (SMMC-7721, MHCC-97L, and Hep3B)
expressing lower levels of MAOA than in cells (SK-Hep1) express-
ing relatively higher levels of MAOA (Fig. 4A).
SMMC-7721cells,whichhavehigher levels of EGFR transactiva-
tion following NE stimulation were used to further investigate the
effects of MAOA on ADR-mediated EGFR transactivation (Fig. 4B).
The results indicated that bothNE and EGF can induce EGFR activa-
tion in SMMC-7721 cells,whileMAOAoverexpression signiﬁcantly
suppressed NE-, but not EGF-, induced EGFR phosphorylation and
the downstream activation ofMAPK/extracellular signal-regulated
kinase (Erk1/2) (Fig. 4B and Supplementary Fig. 7).
Prazosin and ICI118551 were used to determine whether NE-
induced EGFR transactivation is mediated via a1A- or b2-ADRs in
SMMC-7721 cells. We found that both prazosin and ICI118551
reduced NE-induced EGFR phosphorylation. Similar inhibitory
effects were also observed by using EGFR inhibitors AG1478
(100 nmol/L) and erlotinib (100 nmol/L). Additionally, protein
kinase A (PKA), a canonical effector of NE-ADR signaling, was
shown to be activated by NE stimulation (which was suppressed
by treatment with ADR antagonists, but not EGFR inhibitors)
(Fig. 4C). MAOA overexpression can suppress both NE-induced
PKA activation and EGFR transactivation (Fig. 4C).MMP7, ADAM12, and HB-EGF are involved in NE-induced EGFR
transactivation
GPCR-mediated EGFR transactivation requires either speciﬁc
metalloproteinases (MMPs) or disintegrin and metalloprotein-
ases (ADAMs) to cleave EGF-like ligands [21,23]. To identify
which MMPs, ADAMs or EGF-like ligands were involved in NE-
induced transactivation of EGFR, we performed genome-wide
cDNA microarrays with vehicle-treated Lenti-vector/SMMC-
7721 cells, NE-treated Lenti-vector/SMMC-7721 cells and NE-
treated Lenti-MAOA/SMMC-7721 cells. The results showed that
MMP7, ADAM12, and HB-EGF expression were upregulated byvol. 60 j 1225–1234
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Fig. 2. MAOA overexpression abrogates the effects of epinephrine (E) or norepinephrine (NE) on HCC cell invasion and anoikis inhibition in vitro and metastasis
in vivo. (A and B, upper) Representative quantiﬁcation of cell invasiveness analysis of SMMC-7721 (A) and MHCC-97L (B) cells infected with Lenti-MAOA and Lenti-vector,
stimulated by E or NE. (A and B, lower) Flow cytometry statistical analysis of anoikis of SMMC-7721 (A) and MHCC-97L (B) cells infected with Lenti-MAOA and Lenti-vector,
stimulated by E or NE. (C) Representative images of H&E staining in liver tissues from mice orthotopically inoculated with MAOA overexpressed SMMC-7721 and control
cells. Statistical analysis of intrahepatic metastatic focis (200) in the two groups is shown right. (D) Pulmonary metastases were detected by H&E staining. Statistical
analysis of numbers of pulmonary metastatic nodules (200) is shown right. (E) H&E staining of intrahepatic tumors and metastases in mice orthotopically inoculated with
SK-Hep1 cells and intraperitoneally injected with clorgyline or vehicle. Statistical analysis of intrahepatic metastatic focis (200) in the two groups is shown right. Arrows:
intrahepatic or pulmonary metastases. Scale bars, 10 lm ⁄p <0.05, ⁄⁄p <0.01.
JOURNAL OF HEPATOLOGYNE stimulation and this upregulation was abrogated by MAOA
overexpression. But the expression of MMP2, MMP9, ADAM10,
ADAM17, amphiregulin, and TGF-alpha were not altered by NE
stimulation or MAOA overexpression (Table 3). These results
were further conﬁrmed with real-time PCR analyses (Fig. 4D).
In addition, the activity of ADAM17, the main metalloprotease
responsible for the shedding of the EGFR ligands, was unchanged
under NE stimulation by measuring the activity of TACE/ADAM17
with ﬂuorogenic substrate (Supplementary Fig. 8).
To further conﬁrm that MMP7 and ADAM12 are the major
proteinases involved in NE-induced transactivation of EGFR, weJournal of Hepatology 2014use RNA interference to knock-down their expression and spe-
ciﬁc inhibitors to block their activities. The results showed that
NE-induced phosphorylation of EGFR was obviously suppressed
by silencing of MMP7 or ADAM12 (Fig. 4E). The effects of NE on
HCC cell invasion and anoikis were also abrogated by silencing
of MMP7 or ADAM12 (Supplementary Fig. 9B and C). Additionally,
similar results were obtained by application of MMP inhibitor III
(a MMP7 inhibitor, 10 lmol/L) and GM6001 (a MMP7/ADAM12
inhibitor, 25 lmol/L) (Fig. 4F and Supplementary Fig. 9D and E).
To conﬁrm that HB-EGF is the major EGF-like ligand involved
in NE-induced EGFR transactivation in HCC cells, we furthervol. 60 j 1225–1234 1229
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Fig. 3. The expression of MAOA is inversely correlated with NE/E content in HCC tissues, and NE-induced HCC cell invasion and anoikis inhibition were mediated by
different adrenoceptors. (A) Analysis of correlation between the mRNA level of MAOA and the content of NE in 19 cases of human HCC tissues. Pearson’s correlation was
used. (B) Analysis of correlation between the mRNA level of MAOA and the content of E. (C) Statistical analysis of NE and E content in 35 cases of HCC tissues ⁄⁄p <0.01. (D)
The expression of MAOA protein in the culture supernatant of control or MAOA overexpressed SMMC-7721 or MHCC-97L cells. GAPDH of remaining cells was used as a
loading control. (E and F) SMMC-7721 (E) or MHCC-97L cells (F), pre-treated with prazosin or ICI118551, were analyzed for cell invasiveness or anoikis upon 100 nM NE
stimulation. (G and H) NE-induced invasion and anoikis inhibition of SMMC-7721 (G) and MHCC-97L (H) were signiﬁcantly reduced by ADRA1A or ADRB2 knockdown n.s.,
not signiﬁcant ⁄p <0.05, ⁄⁄p <0.01.
Research Articlecompared the levels of HB-EGF, amphiregulin, and TGF-alpha in
the extracellular medium of Lenti-vector/SMMC-7721 cells and
Lenti-MAOA/SMMC-7721 cells treated with NE at 0 min, 5 min,
10 min, and 15 min, respectively. It was found that the amount
of HB-EGF in the extracellular medium was signiﬁcantly higher
than that of amphiregulin or TGF-alpha. Furthermore, HB-EGF
release was signiﬁcantly increased by NE stimulation, and
decreased by MAOA overexpression (Supplementary Fig. 9A).
The results also showed that the level of TGF-alpha was slightly
increased by NE stimulation and was decreased by MAOA
overexpression, indicating that TGF-alpha might also contribute
to NE-induced EGFR transactivation (Supplementary Fig. 9A).
Furthermore, NE-induced phosphorylation of EGFR was obvi-
ously reduced by HB-EGF blockade with HB-EGF neutralyzing
antibody (5 lg/ml) or heparin (100 lg/ml) (Fig. 4G). NE-induced1230 Journal of Hepatology 2014HCC cell invasion and anoikis inhibition were also suppressed by
blocking HB-EGF (Supplementary Fig. 9F and G). To further con-
ﬁrm that EGFR is required for NE-induced HCC cell invasion
and anoikis inhibition, we knocked down EGFR with siRNA and
found that the effects of NE on HCC cell invasion and anoikis
was abrogated (Supplementary Fig. 10).
Taken together, these data indicated that MMP7, ADAM12,
and HB-EGF are involved in NE-induced EGFR transactivation.MAOA enhances the inhibitory effects of EGFR inhibitors or ADR
antagonists on NE-induced HCC cell invasion and anoikis inhibition
The persistent release of NE from the sympathetic nerve endings
that occurs during conditions of acute and chronic stress invol. 60 j 1225–1234
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Table 3. cDNA microarray data of MMP7/ADAM12/HB-EGF for Lenti-vector/SMMC-7721 treated with vehicle, Lenti-vector/SMMC-7721 treated with NE and Lenti-
MAOA/SMMC-7721 treated with NE, respectively.
Symbol AVG signal value Fold change
Lenti-vector Lenti-vector
+ NE
Lenti-MAOA
+ NE
Lenti-vector + NE
/lenti-vector
Lenti-MAOA + NE/
lenti-vector + NE
Lenti-MAOA + NE/
lenti-vector
MMP2 0.01 0.01 0.01 1 1 1
MMP7 51.73271 67.87345 31.92715 1.31 0.47 0.62
MMP9 0.01 0.01 0.01 1 1 1
ADAM10 119.0204 136.3069 122.3337 1.15 0.90 1.03
ADAM12 4.338587 21.11914 8.095791 4.87 0.38 1.87
ADAM17 62.67328 82.16988 65.19996 1.31 0.79 1.04
HB-EGF 51.6576 72.02672 52.62322 1.39 0.73 1.02
amphiregulin 0.01 0.01 0.01 1 1 1
TGFα 0.01 0.01 0.01 1 1 1
Research Articlehumans (particularly cancer patients), in addition to the
decreased MAOA expression that occurs in HCC, leads to the aber-
rant accumulation of NE in HCC tissues, which may decrease the
efﬁciency of EGFR-targeting drugs or ADR antagonists during HCC
treatment. We speculate that, by removing NE from the HCC
microenvironment, MAOA may enhance the effects of EGFR
inhibitors or ADR antagonists during HCC. The results indicatedFig. 4. MAOA inhibits ADRA1A/ADRB2-mediated transactivation of EGFR signaling, a
NE-induced HCC cell invasion and anoikis inhibition. (A) Western blotting analysis of
Phosphorylation of EGFR, Erk1/2 in MAOA overexpressed and control SMMC-7721 cells tr
(C) Phosphorylation of EGFR or PKA in SMMC-7721 cells treated with prazosin, ICI11855
and amphiregulin for Lenti-vector/SMMC-7721 treated with vehicle, Lenti-vector/SMMC
Phosphorylation of EGFR induced by NE was obviously suppressed by blocking MMP7
(MMP7/ADAM12 inhibitor) (F). (G) Phosphorylation of EGFR induced by NE was obviou
heparin. (H and I) EGFR inhibitors or ADRs antagonists abrogated NE-induced HCC cell
MAOA overexpression ⁄p <0.05, ⁄⁄p <0.01. (J) Model for NE/E-derived and ADRs-mediated
E, ADRA1A/ADRB2 activates MMP7/ADAM12, release HB-EGF to transactivate EGFR and
ADRA1A/ADRB2-mediated transactivation of EGFR signaling can be blocked by EGFR inhib
better inhibitory effect on ADRs-mediated transactivation of EGFR. Additionally, canoni
1232 Journal of Hepatology 2014that NE-induced HCC cell invasion and anoikis inhibition can be
suppressed by single usage of EGFR inhibitors or ADR antagonists
or MAOA overexpression in SMMC-7721 cells (Fig. 4H) and
MHCC-97L cells (Fig. 4I), which was synergistically suppressed
by combined use of EGFR inhibitors or ADR antagonist with
MAOA overexpressing, compared with that obtained in untreated
transfected cells (Fig. 4H and I).nd enhances the inhibitory effects of EGFR inhibitors or ADRs antagonists on
phosphorylation of EGFR in four different HCC cells treated with NE for 5 min. (B)
eated with NE for 0, 5, 10, and 15 min. GAPDH was detected as the loading control.
1, AG1478, erlotinib and/or NE. (D) PCR analysis of MMP7, ADAM12/HB-EGF, TGF-a,
-7721 treated with NE and Lenti-MAOA/SMMC-7721 treated with NE. (E and F)
or ADAM12 with siRNA (E) or MMP inhibitor III (MMP7 inhibitor) and GM6001
sly suppressed by blocking HB-EGF with anti-HB-EGF neutralyzing antibody and
invasion and anoikis inhibition of SMMC-7721 (H) and MHCC-97L cells (I) with
signalings underlying HCC cell invasiveness and anoikis. Upon stimulation by NE/
downstream Erk1/2 signaling, thereby promote cell invasiveness and anti-anoikis.
itors, ADRs antagonists or MAOA overexpression. Combined use of them obtains a
cal PKA and CREB signaling also participate in this mechanism.
vol. 60 j 1225–1234
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These data indicated that MAOA enhances the inhibitory
effects of EGFR inhibitors or ADR antagonists on NE-induced
HCC cell invasion and anoikis inhibition (Fig. 4J).Discussion
As a catecholamine neurotransmitter degrading enzyme, MAOA
has long been thought to be associated with human emotional
and mental states. However, its functional roles in cancer devel-
opment have rarely been studied. Several studies on prostate
cancer (PCa) had suggested that upregulated MAOA in PCa cells
was positively related to PCa progression [17,18]. On the con-
trary, in cholangiocarcinoma, MAOA was suppressed by the coor-
dinated control of promoter hypermethylation and IL-6 signaling,
and MAOA expression was negatively associated with cancer
invasiveness [19]. These studies suggest the regulation and func-
tion of MAOA vary in different cancer types.
In HCC, DNA copy number aberrations were not found in
Xp11.3, on which MAOA is located [24]. In our research, we dem-
onstrated that MAOA expression was silenced in HCC by epige-
netic methylation and histone acetylation and further identiﬁed
MAOA as a negative regulator of HCC malignancy. To unveil the
underlying mechanism of how MAOA affects HCC invasion and
metastasis, comprehensive studies were performed and the data
indicated that MAOA suppressed HCC cell invasion and metasta-
sis by inhibiting both NE/E-initiated canonical adrenergic signal-
ing and ADR-mediated transactivation of EGFR signaling.
NE/E were known to exert their physiological functions pri-
marily through a- and b-ADRs [25]. In our study, we identiﬁed
that NE/E-induced HCC cell resistance to anoikis was speciﬁcally
mediated by the b2-ADR, which is consistent with the results of
previous ovarian cancer studies [9]. However, NE/E-induced cell
invasion can be mediated by both a1A- and b2-ADRs in HCC.
The adrenergic signaling pathway plays an important role in
cancer progression by regulating multiple cellular processes
[26–28]. Ligation of the b-ADR by NE/E has been reported to stim-
ulate the synthesis of cyclic 30-50 adenosine monophosphate
(cAMP) from adenylyl cyclase, which then activates protein
kinase A (PKA), a cAMP effector, and eventually leads to the phos-
phorylation of transcription factors, such as the cAMP Response
Element Binding Protein (CREB) [26,29,30]. Moreover, in the car-
diovascular system, ADRs can transactivate EGFR signaling via
the proteolysis of latent ligands, such as HB-EGF, by speciﬁc
MMPs or ADAMs [21,23,31–33]. In the present study, we demon-
strated for the ﬁrst time that the ADRA1A/ADRB2 receptors can
transactivate EGFR signaling in cancer.
Because the EGFR is overexpressed in themajority of adenocar-
cinomas and squamous cell carcinomas, the EGFR can be targeted
by selective pharmacological inhibitors that are currently being
used in clinical trials. Several ongoing clinical trials are currently
using b-ADR antagonists (beta-blockers) as anti-cancer drugs
[34–36]. And the use of beta-blockers has been reported to prevent
disease progression in breast cancers and malignant melanomas
[37–39]. Here, we showed that EGFR inhibitors and ADR antago-
nists can inhibit NE/E-induced EGFR transactivation andHCC inva-
sion, as well as prevent anoikis. Notably, we found that MAOA
synergized with EGFR inhibitors or ADR antagonists to abrogate
HCC invasion andpromote anoikis (Fig. 4J). The results of our study
revealed that EGFR inhibitors and ADR antagonists have superior
inhibitory effects in HCC cells that have been transfected with
the MAOA gene compared to the untransfected controls.Journal of Hepatology 2014The current approach to developing drugs for the prevention
and treatment of cancer is to ﬁrst test the effects of the drugs
on cancer cell viability in vitro and to then conduct in vivo tests
in mouse xenografts or experimental tumor models in laboratory
rodents [29]. However, the effects of neurotransmitters, which
are powerful upstream regulators, have been completely ignored.
Thus, many studies, including ours, have suggested that the neu-
rotransmitter system should be considered to be an important
factor for future drug development and drug testing during clin-
ical trials.
Taken together, we described MAOA as a key player in the
adrenergic system in the control of invasion, anoikis, metastasis
and clinical outcomes during human HCC. The results of our
study have provided insight into the application of MAOA as a
novel predictor of clinical outcomes and indicate that increasing
MAOA expression or enzyme activity by using small molecules or
by targeting gene-delivery systems through gene transfer may be
novel approaches that can be used for the treatment of HCC.Financial support
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